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Background: As patients with juvenile idiopathic arthritis (JIA) progress into adulthood, long-term outcome is
determined by disease activity, physical and psychosocial development. Decreased aerobic capacity may play a
critical role in health-related outcomes in JIA, since it has been linked with cardiovascular morbidity and mortality in
late adulthood. The objectives of the current study are to examine the aerobic capacity and its relation to
parameters of disease activity in children, adolescents and young adults with JIA.
Methods: Sixty-three patients with JIA (aged 10–27 years) were cross sectional studied regarding their aerobic
capacity and correlations were made to demographic, disease-related variables, and medication utilization. in a
cross-sectional study group of 63 patients of all subtypes. Patients were divided in three age groups, 10–13 years;
14–17 years and 18–27 years.
Results: Reduced aerobic capacity is found in clinical remission as well as active disease in all subtypes and all age
groups. Aerobic capacity is more impaired in active disease shown by DAS 28, JADAS 27, ESR and serum
thrombocyte counts. Lower haemoglobin has a negative impact. Long-term used medication including
methotrexate and corticosteroids didn’t influence outcome. There is no association with current sports participation.
Conclusion: Reduced aerobic capacity is present in adolescents and young adults with JIA, both in active disease
and in patients with remission. Measures of aerobic capacity may serve as important outcome measure in JIA.
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Although Juvenile Idiopathic Arthritis (JIA) is generally
thought to have a favourable outcome [1], in reality its
course may be less propitious. At adult age, persistent
disease activity and functional impairment have been
reported in more than half of the patients [2-6].More-
over, disease related chronic inflammation may cause
protein loss and fat accumulation [7], increasing the risk
for obesity and cardiovascular disease in this population
[8]. Systemic inflammation, immune dysfunction and its
treatment[9-12], might also contribute to the increased
mortality rate in JIA [10,11].* Correspondence: N.Wulffraat@umcutrecht.nl
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reproduction in any medium, provided the orIn addition to these disease-related factors[5], fac-
tors influencing morbidity in the general population
must also be considered as they are likely to have
heightened effect on patients with JIA. For example,
low aerobic capacity, a marker of physical fitness,
may play a critical role in health-related outcomes in
JIA since it has been linked with an increased risk of
developing chronic diseases including cardiovascular dis-
eases, diabetes, cancer, hypertension, obesity, depression
and osteoporosis [13], as well as an increased risk of mor-
tality in adults [14].
Physical fitness is a multidimensional concept defined as
a set of attributes that people possess or achieve that relate
to the ability to perform physical activity [15]. It is com-
prised of skill-related (e.g. agility, coordination), health-
related (e.g. cardiovascular capacity), and physiologicall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a powerful predictor of mortality in both healthy and dis-
ease states [17,18]. The gold standard for assessing phys-
ical fitness is the aerobic capacity, commonly defined as
the maximal or peak volume of oxygen uptake (VO2peak)
during an incremental exercise test to exhaustion. VO2peak
is expressed either as an absolute value in liters of
oxygen per minute (l/min) or as a relative value in
milliliters of oxygen per kilogram of bodyweight per
minute (ml/kg/min). The relative value is frequently
used to compare the fitness levels of patients with a
chronic disease including a wide range of ages, body
sizes and disease severity.
Aerobic capacity has been shown to be impaired in both
younger children and adolescents with JIA[19-21]. These
impairments may be associated with a combination of the
condition-related pathophysiology itself, its treatment
(e.g. medications), hypoactivity and subsequent decondi-
tioning [22]. Other potential contributing factors to
reduced aerobic capacity in JIA may include anemia,
reduced cardiac output, and muscular dysfunction [20].
Patients with JIA may suffer from normocytic hypo-
chromic anaemia, which implies lower oxygen transport
capacity of the blood, and hence, impaired oxygen trans-
port to the muscles. A recent study of children with JIA
revealed no significant differences in cardiac output
during exercise between the JIA group and healthy
controls [23]. Muscle atrophy, however, is a common
finding in patients with JIA that may be linked to inactiv-
ity, medication utilization (including glucocorticoids) and
disease activity [24].
Although its usage is generally related to disease activ-
ity and severity, medication itself can indirectly affect
aerobic capacity in patients with JIA through its impact
on body composition. For example, pharmacological
doses of glucocorticoids are associated with protein loss,
bone loss and insulin resistance in both hepatic and
peripheral tissues, leading to impaired carbohydrate
metabolism [18,25].An inverse correlation was found
between duration of MTX treatment and respiratory
muscle function in children with systemic and polyar-
ticular JIA, possibly explained by a more severe disease
course being associated with long-term MTX treat-
ment [26] In contrast to observed findings in adult
rheumatoid arthritis (RA) patients [27], in children
with JIA, impairment of lung function by MTX is
rare[28,29]. Effects of anti-TNF therapy on aerobic
capacity are not known yet.
To our knowledge, data on aerobic capacity in relation
to the disease activity in patients with JIA are scarce
[30]. The aims of our current study are therefore to
examine the aerobic capacity and its relation to para-
meters of disease activity in children, adolescents and
young adults with JIA.Methods
All consecutive patients between 2005 and 2008 with
JIA (as classified by the International League Against
Rheumatism criteria, ILAR{Petty, Southwood, et al. 2004
163/id[31]) between the ages of 10 to 27 years were
asked to participate in an observational longitudinal co-
hort study, investigating clinical parameters and aerobic
capacity in children, adolescents and young adults with
JIA over a 3-year period. A total of 63 patients provided
informed consent. The results of baseline assessments
are described in the present study. All patients were seen
in the out-patient clinics of the paediatric or adult depart-
ments of rheumatology & immunology at the University
Medical Center (UMC) Utrecht. Patients were divided
into three age groups, 10–13 years, 14–17 years and
18–27 years, with the latter patient group recruited
from the adult rheumatology department. The middle
age group (14–17 years) will be transferred to adult
health care over the course of the three-year follow-
up study. The Medical-Ethics Committee of the UMC
Utrecht approved all study procedures.
Demographic variables, disease characteristics and medi-
cation utilization (past and current) were recorded for all
patients (Table 1). Functional ability was assessed with the
validated Dutch version of the Childhood Health Assess-
ment Questionnaire [32-34]. Patients were asked about
which sports and leisure activities were performed and the
time consuming per week in a general interview [35]. Phys-
ical examination included a general assessment. Standard
laboratory values including Erythrocyte Sedimentation
Rate (ESR), C - reactive protein (CRP), thrombocytes and
haemoglobin were obtained from a blood sample collected
at the outpatient clinic. Haemoglobin counts were used to
classify anaemia based on international reference values
for in children and adolescents [36].
Aerobic capacity
Aerobic capacity (VO2peak) was assessed using a graded car-
diopulmonary exercise test (CPET) to volitional exhaustion
performed on an electronically braked cycle ergometer
(Lode examiner, Lode BV, Groningen, the Netherlands).
The seat height was adjusted to the patient’s comfort.
Patients began cycling at a workload of 0 Watts and this
increased by 20 Watts every minute until they were no
longer able to continue cycling due to volitional exhaustion,
despite strong verbal encouragement. Patients breathed
through a mouthpiece, which was connected to a calibrated
metabolic cart (Oxycon Pro, Care Fusion, Houten, the
Netherlands). Expired gases were collected and analysed for
breath-by-breath minute ventilation (Ve), oxygen uptake
(VO2), carbon dioxide exhalation (VCO2) and respiratory
exchange ratio (RER; =VCO2/VO2) using conventional
equations. The highest achieved oxygen uptake aver-
aged over a 30-second period was taken as VO2peak.
Table 1 Demographic and disease related variables
N=number of patients Age 10–13 yrs N= 33 Age 14–17 yrs N= 18 Age 18–27 yrs N= 12 All patients N = 63
Boys (N) 13 6 3 22
Girls (N) 20 12 9 41
Subtype JIA N (%)
Systemic 3 (9.1) 4 (22.2) 1 (8.3) 8 (12.7)
Oligo persistent 3 (9.1) 0 (0) 0(0) 3 (4.8)
Oligo extended 9 (27.3) 3 (16.7) 3 (25.0) 15 (23.8)
Polyarticular RF+ 3 (9.1) 2 (11.1) 2 (16.7) 7 (11.1)
Polyarticular RF- 14 (42.4) 8 (44.4) 5 (41.7) 27 (42.9)
Enthesitis related 0 (0) 1 (5.6) 1 (8.3) 2 (3.2)
Psoriatic arthritis 1 (3.0) 0 (0) 0 (0) 1 (1.6)
Disease Duration in years (IQR) 5.5 (6.0) 10.5 (6.0) 10.0 (18.0) 8.0 (7.0)
CHAQ (IQR) 1,6 (0.8) 1,4 (0.3) 1,4 (0.6)_ 1,5 (0.8)
Sports performance (hours/week, IOR) 2.0 (3.0) 3.0 (8.0) 2.5 (6.0) 2.0 (3.0)
BMI kg/m2 (IQR) 17.9 (3.3) 21.3 (4.5) 19.8 (3.9) 18.8 (4.7)
Z-score VO2peak (IQR) −0.9 (1.5) −0.8 (1.6) −0.6 (1.7) −0.8 (1.3)**
Z-score VO2peak/kg (IQR) −1.6 (1.7) −1.5 (2.1) −1.0 (2.1) −1.5 (1.9)**
ESR mm (IQR) 8.0 (10.0) 9.5 (16.0) 7.0 (14.0) 8.0 (13.0)
CRP mg/l (IQR) 2.0 (5.0) 6.0 (23.0) 6.0 (5.0) 5.5 (6.0)
Haemoglobin mmol/l (IQR) 8.0 (1.0) 7.6 (1.0) 8.7 (1.3) 7.9 (1.3)
Thrombocytes 10.9/l (IQR) 315 (102) 273 (102) 290 (93) 298 (83)
DAS28 (IQR) 1.7 (1.1) 1.8 (1.9) 1.5 (1.6) 1.6 (1.2)
JADAS 27 (IQR) 3.6 (7.1) 3.0 (22.9) 2.6 (17.1) 2.9 (9.0)
VAS patient (IQR) 0.2 (2.3) 0.5 (3.1) 0.5 (.6) 0.5 (2.3)
Number of swollen joints (IQR) 0.0 (2.0) 0.0 (3.0) 0.0 (3.0) 0.0 (4.4)
Number of tender joints (IQR) 0.0 (3.5) 0.0 (4.0) 0.0 (3.8) 0.0 (4.1)
Number of limited joints (IQR) 1.5 (4.0) 2.0 (5.0) 2.5 (5.0) 2.0 (4.0)
All variables are expressed as median values unless otherwise stated.
Abbreviations
JIA: Juvenile Idiopathic Arthritis; IQR: interquartile range; CHAQ: Childhood Health Assessment Questionnaire; Sports performance ref:[35] BMI: Body Mass Index;
Z-score: standard deviation of the individual patient compared with values from age- and sex- related historical Dutch controls [37]; VO2peak abs: highest oxygen
uptake in liters of oxygen per minute (l/min) during maximum exercise test in l/min; VO2peak/kg : highest oxygen uptake in milliliters of oxygen per kilogram of
bodyweight per minute (ml/min/kg) during maximum exercise; ESR: Erythrocyte Sedimentation Rate; CRP: C-Reactive Protein; DAS28: Disease Activity Score of 28
joints; JADAS 27: Juvenile Arthritis Disease Activity Score of 27 joints; VAS patient: Visual Analogue Scale of General Health.
** p < 0.01 significant difference compared to healthy age and sex related individuals.
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ECG. To allow comparison of aerobic capacity with healthy
controls, standardized z-scores were determined using:
Z-scores= [(observed VO2peak - predicted VO2peak)/SD]
where predicted VO2peak values were obtained from a
database of established values for age- and gender- related
Dutch controls [37]. A z-score of zero represents a VO2
similar to that of healthy controls, while a score of ±1.5 is
a clinical important difference from healthy controls.
Disease activity
A number of indicators were used to assess disease ac-
tivity including the total number of swollen joints, num-
ber of painful joints, the number of joints with limited
range of motion, number of active joints (defined as
joints with swelling and/or pain during motion), theJuvenile Arthritis Disease Activity Score (JADAS 27)
[38]and the Disease Activity Index 28 (DAS28)[39]. All
of the examinations were performed by an experienced
(paediatric) rheumatologist. Furthermore, a global as-
sessment was performed by the patient (well being; VAS
patient 0-100 mm) as well by a (paediatric) rheumatolo-
gist (disease activity; PGA 0-100 mm). Given that
patients were recruited from both the paediatric and
adult clinics, disease activity scores commonly used in
both the paediatric and adult departments were com-
puted. In adult Rheumatoid Arthritis (RA) patients, the
DAS28 is a commonly used and validated tool to meas-
ure disease activity [39]. This is a compound score of
the number of a total of swollen joints (out of 28), the
number of a total of painful joints (out of 28), assess-
ment of patient’s general health and the erythrocyte
Figure 1 Aerobic capacity (expressed as median Z-score of
VO2peak and VO2peak/kg) in relation to age in adolescents and
young adults with JIA. Z scores are compared to age and sex
related healthy controls (p-values <0.01). Abbreviations: Z-score:
standard deviation of the individual patient compared with values
from age- and sex- related historical Dutch controls [37]; VO2peak abs:
highest oxygen uptake in liters of oxygen per minute (l/min) during
maximum exercise test in l/min; VO2peak/kgl : highest oxygen uptake
in milliliters of oxygen per kilogram of bodyweight per minute (ml/
min/kg) during maximum exercise.
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tivity scores were recently introduced in paediatric
rheumatology: Juvenile Arthritis Disease Activity Score
(JADAS) 10, JADAS 27 and JADAS 71[38]. We utilised
the JADAS 27 compound score because of its feasibility.
Moreover, statistical performance of JADAS 27 is com-
parable to JADAS 71, while the construct validity of
JADAS 10 is poor compared to JADAS 71 and JADAS
27 [38]. The JADAS 27 may present an advantage over
the DAS 28 because it includes measures for the cervical
spine, hips and ankles, joints which are often affected in
(adult) patients with JIA.
Medication use
Past and current medication utilization was obtained
from a review of the patient’s medical chart.
Statistical analysis
All statistical analyses were performed using Statistical
Package for Social Science (SPSS) version 15.0 for win-
dows (SPSS Inc., Chicago, IL) version 15.0 for Windows.
Because patient data were non normally distributed non-
parametric tests were used to analyse the demographic
variables and compare the results of the cardiopulmonary
exercise tests (Mann–Whitney and Kruskal-Wallis where
appropriate). Spearman’s Correlation test was used for de-
termining the correlations between VO2peak and disease
activity markers and standard laboratory values. The level
of statistical significance was set at P < 0.05.
Results
Demographics
Demographic and disease related characteristics are pre-
sented in Table 1. In total, 22 boys and 41 girls partici-
pated in the study. The longest disease durations were
seen in the oldest age group. No significant differences
were noted between age groups with respect to disease
duration, body mass index (BMI), disease activity markers
as measured by number of swollen and tender joints,
DAS28, JADAS 27 and laboratory values.
Aerobic capacity
The median peak heart rate was 187 beats per minute
(Interquartile range [IQR] 17), indicating an adequate
level of maximum achieved exercise. The median aer-
obic capacity in all patients with JIA was considerably
lower compared to healthy peers, with a median z-score
of −0.8 (p < 0.01) for absolute VO2peak (L/min) and −1.5
(p < 0.01) for relative VO2peak/kg (ml/kg/min) in all
patients. VO2peak did not differ significantly by gender,
disease duration or JIA sub-type; therefore all patients
were merged for further analysis. There were no statis-
tical significant differences in the z-scores for absoluteand relative VO2peak between the different age groups
(Figure 1).
Aerobic capacity and disease activity
Spearman’s correlation coefficient revealed a significant
negative correlation between the number of swollen
joints and absolute VO2peak z-score, but not with relative
VO2peak z-score (Table 2). No significant correlations
were seen between VO2peak values and the number of
painful joints (Table 2). Both disease severity compound
scores (DAS28 and JADAS 27) showed significant mod-
erately strong negative associations with all VO2peak
values (Table 2).
A substantial proportion of the patients presented with
low disease activity as reflected by low median numbers
of swollen and painful joints (Table 2). The patients were
divided into 2 groups based on disease activity status,
these included patients in remission or inactive disease
(defined by Wallace et al. [40], active joint count zero;
DAS28 ≤2.6) and a patient group with disease activity
(active joint count one and higher; DAS28 > 2.6)[40,41].
Between these patient groups, significant differences as
measured by active joint count and DAS28 score were
seen (Figure 2).
Table 2 Median values (IQR) of Disease activity markers and Spearman’s Correlation Coefficient values for Aerobic
Capacity (expressed by absolute and relative VO2 peak) (level of significance:* indicates significance < 0.05; **
indicates significance <0.01)
Median (IQR) Correlation Z-score VO2peak
(p -value)
Correlation Z–score VO2peak/kg
(p -value)
Number of swollen joints in lower extremities 0.0 (0) −0.3 (**) −0.1
number of swollen joints in upper and lower extremities 0.0 (2) −0.3 (**) −0.1
Number of painful joints lower extremities 0.0 (2) −0.1 −0.1
number of painful joints in upper and lower extremities 0.0 (4.0) −0.2 −0.1
number of limited joints in upper and lower extremities 2.0 (4.0)) −0.3 (*) −0.3 (*)
Active joint count 0.0 (0) −0.3 (**) −0.2
VAS patient 0.5 (2.6) −0.3 (*) −0.3 (*)
DAS28 1.6 (1.2) −0.4 (**) −0.4 (**)
JADAS 27 2.9 (9.0) −0.3(**) −0.4(**)
Abbreviations
IQR: interquartile range, Z-score: standard deviation of the individual patient compared with values from age- and sex- related historical Dutch controls(37);
VO2peak abs: highest oxygen uptake in liters of oxygen per minute (l/min) during maximum exercise test in l/min; VO2peak/kgl : highest oxygen uptake in milliliters
of oxygen per kilogram of bodyweight per minute (ml/min/kg) during maximum exercise; VAS patient: Visual Analogue Scale of General Health (0-100 mm);
DAS28: Disease Activity Score of 28 joints; JADAS 27: Juvenile Arthritis Disease Activity Score of 27 joints.
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tween laboratory parameters reflecting disease activity
(ESR, thrombocytes) and the aerobic capacity (Table 3).Figure 2 Aerobic capacity (expressed as Z-score of VO2peak and
VO2peak/kg) in relation to disease activity in adolescents and
young adults with JIA in remission and with active disease.
Z scores are compared to age and sex matched healthy controls
(* p-values <0.05; **p-values <0.01). Abbreviations: Z-score: standard
deviation of the individual patient compared with values from
age- and sex- related historical Dutch controls [37]; VO2peak abs:
highest oxygen uptake in liters of oxygen per minute (l/min) during
maximum exercise test in l/min; VO2peak/kgl : highest oxygen uptake
in milliliters of oxygen per kilogram of bodyweight per minute
(ml/min/kg) during maximum exercise; AJC: Active Joint Count;
DAS28: Disease Activity Score of 28 joints.Conversely, no relationship was seen between C-reactive
protein, an acute phase protein and VO2peak (Table 3). We
found a positive significant correlation between serum
haemoglobin and the relative VO2peak/kg in boys as well in
the total patient group. In girls, a positive significant correl-
ation between serum haemoglobin and the absolute
VO2peak (p<0.05, Table 3) was observed. Lower VO2peak
and VO2peak/kg values were noted in patients with anaemia
compared to those who were not anaemic (p <0.05).
Aerobic capacity and use of disease modifying
anti-rheumatic drugs (DMARD)
Thirteen of our patients were not using any DMARD at the
time of the testing, 38 patients were using one DMARD, 11
patients were using a combination of two DMARD’s and
only 1 patient was on a combination therapy of three
DMARD’s. Non-parametric tests revealed no significant dif-
ferences in aerobic capacity between these patients. No sig-
nificant correlations were found between current use of
DMARD and absolute and relative VO2peak values. When
looking at historical DMARD use, only use of anti-Tumor
Necrosing Factor biologicals in 10 patients was significantly
associated with lower absolute and relative VO2peak values
(p<0.05). Duration of current and formerly MTX use did
not affect aerobic capacity.
A total of 6 patients were currently using corticoster-
oids at the time of testing, while 10 patients had used
them the past and 47 patients never used corticoster-
oids. Neither current nor former corticosteroid use was
significantly related to aerobic capacity.
Discussion
Although a favorable long-term outcome is seen in
about half of the patients with JIA [1], results of the
Table 3 Median (IQR) Standard Laboratory Values and
Spearman’s Correlation Coefficients for Aerobic Capacity
(expressed by absolute and relative VO2 peak) (level of
significance:* indicates significance <0.05; ** indicates
significance <0.01)
Median
(IQR)
Correlation with
Z-score VO2peak
(p -value)
Correlation Z-score
VO2peak/kg
(p -value)
ESR (mm) 8.0 (13) −0.3 (*) −0.5 (**)
CRP (mg/l) 5.5 (6) −0.2 −0.2
Thrombocytes
(10.9/l)
302 (110) −0.4 (**) −0.5(**)
Haemoglobin
(mmol/l) boys
8.1 (1.2) +0.0 +0.5 (*)
Haemoglobin
(mmol/l) girls
7.8 (1.1) +0.3 (*) +0.2
Abbreviations
IQR: Interquartile Range; Z-score: standard deviation of the individual patient
compared with values from age- and sex- related historical Dutch controls(37);
VO2peak abs: highest oxygen uptake in liters of oxygen per minute (l/min)
during maximum exercise test in l/min; VO2peak/kgl : highest oxygen uptake in
milliliters of oxygen per kilogram of bodyweight per minute (ml/min/kg)
during maximum exercise; ESR: Erythrocyte Sedimentation Rate (ref 2-12 mm
in 1 hour); CRP: C-Reactive Protein (ref 0–10 milligram per litre); thrombocytes
(ref 150–450 10.9 per litre); Haemoglobin boys (ref: age group 10-12 yrs:
6.6-.8.4 millimol per liter age 12–18 yrs 6.9-9.1 millimol per liter; age >18 yrs:
8.6-10.5 millimol per liter); Hemoglobin girls (ref: age 10–12 yrs 6.6-8.4 millimol
per liter; age 12–18 yrs 6.8-8.3 millimol per liter; age >18 yrs:7.5-9.5 millimol
per liter).
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obic capacity, with a median z score of −1.5 in all patients
(children, adolescents and young adults with JIA. Al-
though disease duration and DMARD use were expected
to have a negative influence on aerobic capacity, no sig-
nificant correlations, with the exception of past biological
use were seen between these variables.
Despite the overall low median disease activity in our
patient group, representing the general favorable disease
outcome, aerobic capacity was still significantly reduced in
patients with JIA compared to healthy controls. Significant
impairments in aerobic capacity have previously been
reported in youth with other chronic diseases including
Crohn’ disease and dermatomyositis [42-44]. A significant
correlation of disease activity with aerobic capacity was
found (Table 2), the strongest correlations were seen for
the compound scores DAS28 and JADAS27. When con-
sidering separate items, aerobic capacity was significantly
related to the number of swollen, limited, and active
joints, but not to the number of painful joints. Apparently,
joint-pain is a negligible limiting factor in reaching a max-
imum of exercise levels.
When the study population was divided by disease ac-
tivity status, (remission or inactive disease [40] versus
active disease) significant differences in aerobic capacity
were observed (Figure 2). Since a lower aerobic capacity
was also noted in patients in remission compared with
healthy controls, one might hypothesize that currentindicators of disease activity in JIA are not always suffi-
cient to predict impaired aerobic capacity. As low aerobic
capacity is linked with an increased risk of developing
other chronic diseases including cardiovascular diseases,
diabetes, cancer, hypertension, obesity, depression and
osteoporosis [13], as well as an increased risk of mortality
in adults [14], this current finding is of importance for the
quality of life of all patients with JIA.
Significantly negative correlations were observed be-
tween ESR, thrombocytes and both absolute and relative
aerobic capacity, suggesting that disease activity and sys-
temic inflammation may negatively affect aerobic capacity.
Extensive studies on the role of inflammatory cytokines
(e.g. TNF-α) in maintaining the balance between muscle
protein synthesis and degradation [7] have lead to the
concept of rheumatoid cachexia, a condition in which
muscle protein degradation is favored over synthesis
resulting in muscle wasting, impaired muscle strength and
a concomitant increase of fat mass. Body mass index was
used as an indirect parameter of body composition in the
current study, but did not reveal any significant relation-
ship with aerobic capacity. Although it has been described
a common complication in JIA [45], we did not find a sig-
nificant growth retardation (median length 50th percentile;
median weight 49th percentile) in our population.
Future studies in patients with JIA might also consider
the inclusion of detailed determination of body compos-
ition (muscle mass, fat mass and bone mass) next to
muscle strength testing.
This is the first study in patients with JIA to show
lower aerobic capacity in individuals with lower serum
hemoglobin .This correlation may be explained by a lower
oxygen transport capacity to the muscles. In chronic con-
ditions like end-stage kidney disease, anemia is thought to
at least partly explain the observed reduction in aerobic
capacity [46]. Anemia is often considered a reflection of
disease activity [47], suggesting that perhaps the observed
correlation with aerobic capacity is due to disease activity,
rather than anaemia per se; however, this relationship
remained significant when the data were corrected for dis-
ease activity.
In our study, no evidence for the influence of any
DMARD or glucocorticoids intake on aerobic capacity
was found, and also duration of MTX treatment was not
correlated with VO2peak. Although in earlier days MTX
treatment was limited to more severe disease course, in
our study population, MTX is used in all subtypes of JIA
and in almost all patients (61 out of 63 patients). Only
past anti-TNF biological therapy appeared to negatively
influence aerobic capacity; this may be related to the fact
that anti-TNF in the Netherlands is restricted to patients
with a poly-articular disease course after failure of treat-
ment with, or untreatable side effects of high dose MTX.
This suggests that a more severe disease course, rather
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aerobic capacity. It is important to note that despite our
finding of similar disease activity among all JIA subtypes
and DMARD utilization, generally patients with a poly-
articular and systemic JIA are considered to have a more
severe disease course.
In longstanding JIA muscle atrophy, decreased muscle
strength and lower extremity deformities might serve to
limit aerobic capacity. Moreover much like adults with RA,
patients with JIA may have low levels of physical activity
(hypo activity)[22], highlighting the need for more rigorous
training programs in this population to prevent the
increased risk of developing chronic diseases like cardiovas-
cular disease and diabetes [13,48,49]. In the present study,
approximately 73% of the patients reported participating in
sport more than 12 times a year, compared with 68% in
general population [35]. In our study, sport participation
was not significantly correlated with aerobic capacity
(results not shown).
We realize that the current patient group represents a se-
lect group of patients that may not be reflective of the gen-
eral pediatric and young adult rheumatology population.
More specifically, since the patients in our study, are at
least 10 years of age, the percentage of persistent oligo-
articular patients is lower than the proportion typically seen
in the pediatric outpatient clinic. Despite this patient
selection, it is remarkable that a negative correlation was
observed between disease activity and aerobic capacity,
which persisted into adulthood. Furthermore it is also im-
portant to note that although a number of correlations pre-
sented were only moderately strong, they remained
significant and were consistent across several markers that
reflect disease activity, namely DAS 28, JADAS 27, and la-
boratory markers like ESR, thrombocytes and hemoglobin.
Conclusions
In conclusion, our results demonstrate that children, ado-
lescents and young adults with JIA suffer from reduced
aerobic capacity. This impairment in aerobic capacity was
seen in patients with active disease as well as those in re-
mission. Further, we report that aerobic capacity is nega-
tively correlated to disease activity, as measured by
physical examination as well as several laboratory para-
meters. Given that poor aerobic capacity has been linked
with a number of healthy complications, these findings
highlight the need for longstanding follow up into adult-
hood of patients with JIA, even if disease activity is low or
in remission.
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